Treats pulmonary arterial hypertension (PAH) (WHO Group 1). Sold as Letairis. Every FDA application for this active ingredient: 1 branded and 9 generic.
As of Nov 16, 2026, FDA lists 10 applications for Ambrisentan (sold as Letairis), first approved Jun 15, 2007, with 2 new uses approved and 0 published complete response letters.
| Ambrisentan | Part D | $127M | -32% | 7,117 |
| Letairis | Part D | $65.2M | -21% | 511 |
| COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesPulmonary Arterial Hypertension (PAH), Comorbidities · Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Nov 24, 2025 |
| Nefecon and Ambrisentan in IgA NephropathyIgA Nephropathy, Chronic Kidney Disease · The First Hospital of Jilin University | Phase 4 | Recruiting | Jun 22, 2025 |
| The Impact of ERA Switching on Risk Stratification in Pulmonary Arterial HypertensionPulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) · University of Sao Paulo General Hospital | — | Recruiting | Jun 10, 2025 |
| Ambrisentan for Early Low-Risk Pulmonary Arterial HypertensionPulmonary Arterial Hypertension (PAH) · Nanjing First Hospital, Nanjing Medical University | Not applicable | Not yet recruiting | May 23, 2025 |
| Comparison of Sequential to Initial Combination Therapy in PAHPulmonary Arterial Hypertension (PAH) · Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Recruiting | May 13, 2025 |
| Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I PatientsPulmonary Arterial Hypertension · AOP Orphan Pharmaceuticals AG | Phase 4 | Recruiting | Mar 19, 2024 |
| Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal SyndromeHepatorenal Syndrome, Liver Cirrhosis · Noorik Biopharmaceuticals AG | Phase 2 | Active, not recruiting | Feb 13, 2024 |
| Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionPulmonary Arterial Hypertension · Actelion | Phase 3 | Active, not recruiting | Feb 18, 2020 |
| Jun 15, 2007 | LetairisNDA 22081 · New molecular entity | Gilead | 33 | Marketed |
| Mar 28, 2019 | AmbrisentanANDA 208252 | Watson Labs Inc | 6 | Marketed |
| Mar 28, 2019 | AmbrisentanANDA 208441 | Mylan | 6 | Marketed |
| Mar 28, 2019 | AmbrisentanANDA 210058 | Zydus Pharms | 9 | Marketed |
| Mar 28, 2019 | AmbrisentanANDA 210784 | Sun Pharm | 7 | Discontinued |
| Apr 10, 2019 | AmbrisentanANDA 208354 | Sigmapharm Labs LLC | 5 | Marketed |
| Apr 10, 2019 | AmbrisentanANDA 209509 | Ph Health | 5 | Discontinued |
| Apr 26, 2019 | AmbrisentanANDA 210715 | Cipla | 7 | Marketed |
| May 19, 2022 | AmbrisentanANDA 210701 | Apotex | 3 | Marketed |
| Jul 21, 2022 | AmbrisentanANDA 216531 | Aurobindo Pharma | 3 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA